ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,039.31
-0.47%
US Tech 100
20,872.00
0.00%
다우존스 지수
44,713.52
-0.31%
Bitcoin
103,822.00
2.45%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Rigel Pharmaceuticals Inc (RIGL) 시세

Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (RIGL)

NASDAQ
22.49
0.33
(1.49%)
종가: 30 1월 6:00AM
15분 지연
22.49
0.00
( 0.00% )
시간외 거래: 6:30AM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
22.49
매수가
22.20
매도가
22.85
거래량
93,035
21.8837 일간 변동폭 22.85
7.4843 52주 범위 29.82
market_cap
396.162M
전일 종가
22.16
개장가
22.02
최근 거래 시간
21
@
22.7986
마지막 거래 시간
06:24:43
재정 규모
US$ 2,080,713
VWAP
22.3648
평균 볼륨(3m)
299,213
발행 주식
17,615,040
배당수익률
-
주가수익률
-15.86
주당순이익(EPS)
-1.42
매출
116.88M
순이익
-25.09M

Rigel Pharmaceuticals Inc 정보

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For mor... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit https://www.rigel.com/. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.rigel.com
본부
Wilmington, Delaware, USA
설립됨
-
Rigel Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker RIGL. The last closing price for Rigel Pharmaceuticals was US$22.16. Over the last year, Rigel Pharmaceuticals shares have traded in a share price range of US$ 7.4843 to US$ 29.82.

Rigel Pharmaceuticals currently has 17,615,040 shares in issue. The market capitalisation of Rigel Pharmaceuticals is US$390.35 million. Rigel Pharmaceuticals has a price to earnings ratio (PE ratio) of -15.86.

RIGL 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

20 시간 전
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

25 1월 2025
Edgar (US Regulatory)

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 First patient enrolled in...

22 1월 2025
PR Newswire (US)

Form 8-K - Current report

13 1월 2025
Edgar (US Regulatory)

Rigel Provides Business Update and 2025 Outlook

Rigel Provides Business Update and 2025 Outlook PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes...

13 1월 2025
PR Newswire (US)

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel...

09 1월 2025
PR Newswire (US)

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 /PRNewswire/ -- Rigel...

08 1월 2025
PR Newswire (US)

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025...

03 1월 2025
PR Newswire (US)

Form 8-K - Current report

10 12월 2024
Edgar (US Regulatory)

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 R289 was...

10 12월 2024
PR Newswire (US)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.472.1344232515922.0223.220.7517661121.91604496CS
44.94328.170057559717.54723.215.523892918.78514629CS
127.4949.93333333331529.8214.4729921320.81534302CS
2611.79110.18691588810.729.828.6120451518.41766266CS
529.6975.70312512.829.827.484374810312.42057876CS
156-1.21-5.1054852320723.735.156.4213524813.53175406CS
260-2.61-10.398406374525.1556.4243642722.81367827CS

RIGL - Frequently Asked Questions (FAQ)

What is the current Rigel Pharmaceuticals share price?
The current share price of Rigel Pharmaceuticals is US$ 22.49
How many Rigel Pharmaceuticals shares are in issue?
Rigel Pharmaceuticals has 17,615,040 shares in issue
What is the market cap of Rigel Pharmaceuticals?
The market capitalisation of Rigel Pharmaceuticals is USD 390.35M
What is the 1 year trading range for Rigel Pharmaceuticals share price?
Rigel Pharmaceuticals has traded in the range of US$ 7.4843 to US$ 29.82 during the past year
What is the PE ratio of Rigel Pharmaceuticals?
The price to earnings ratio of Rigel Pharmaceuticals is -15.86
What is the cash to sales ratio of Rigel Pharmaceuticals?
The cash to sales ratio of Rigel Pharmaceuticals is 3.4
What is the reporting currency for Rigel Pharmaceuticals?
Rigel Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Rigel Pharmaceuticals?
The latest annual turnover of Rigel Pharmaceuticals is USD 116.88M
What is the latest annual profit for Rigel Pharmaceuticals?
The latest annual profit of Rigel Pharmaceuticals is USD -25.09M
What is the registered address of Rigel Pharmaceuticals?
The registered address for Rigel Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Rigel Pharmaceuticals website address?
The website address for Rigel Pharmaceuticals is www.rigel.com
Which industry sector does Rigel Pharmaceuticals operate in?
Rigel Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PCSAProcessa Pharmaceuticals Inc
US$ 0.8626
(45.64%)
479.02k
CARMCarisma Therapeutics Inc
US$ 0.6959
(37.91%)
3.08M
GMHSGamehaus Holdings Inc
US$ 2.50
(30.21%)
48.12k
OSTOstin Technology Group Company Ltd
US$ 3.53
(21.55%)
729.46k
EDSAEdesa Biotech Inc
US$ 2.15
(17.51%)
2.5k
MXLMaxLinear Inc
US$ 18.00
(-17.36%)
57.09k
RFACRF Acquisition Corporation
US$ 5.95
(-14.51%)
353
IKTInhibikase Therapeutics Inc
US$ 2.4201
(-14.18%)
73.39k
DSYBig Tree Cloud Holdings Limited
US$ 1.75
(-10.26%)
1.03k
IFBDInfobird Company Ltd
US$ 1.95
(-10.14%)
160.78k
NVDANVIDIA Corporation
US$ 125.00
(0.98%)
24.18M
VCSHVanguard Short Term Corporate Bond
US$ 78.43
(0.01%)
9.57M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 24.8403
(0.81%)
7.28M
TSLATesla Inc
US$ 389.0253
(0.26%)
5.59M
MGOLMGO Global Inc
US$ 0.112199
(10.11%)
4.39M

RIGL Discussion

게시물 보기
dcaf7 dcaf7 9 월 전
Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
👍️0
Monksdream Monksdream 9 월 전
RIGL under $2
👍️0
Monksdream Monksdream 10 월 전
RIGL under $2
👍️0
dcaf7 dcaf7 10 월 전
Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/
👍️0
dcaf7 dcaf7 10 월 전
Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.
👍️0
dcaf7 dcaf7 11 월 전
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023
👍️0
bme bme 1 년 전
Rigl should be VTGN (Today) one day.
👍️0
bme bme 2 년 전
Yeah. Should be good Q.
👍️0
TucsonPhil TucsonPhil 2 년 전
Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.
👍️0
bme bme 2 년 전
Better be good.
👍️0
bme bme 2 년 전
Ugly.
👍️0
The Night Stalker The Night Stalker 2 년 전
nice
👍️0
The Night Stalker The Night Stalker 2 년 전
nice
👍️0
The Night Stalker The Night Stalker 2 년 전
base
👍️0
bme bme 2 년 전
What a shoot! Amazing.
👍️0
bme bme 2 년 전
The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?
👍️0
The Night Stalker The Night Stalker 2 년 전
nice fins
👍️0
The Night Stalker The Night Stalker 2 년 전
gem
👍️0
The Night Stalker The Night Stalker 2 년 전
gem
👍️0
The Night Stalker The Night Stalker 2 년 전
easy
👍️0
bme bme 2 년 전
Nice spike AH today.
👍️0
bme bme 2 년 전
Higher low higher low.... next leg is North.
👍️0
The Night Stalker The Night Stalker 2 년 전
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
The Night Stalker The Night Stalker 2 년 전
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
bme bme 2 년 전
acting wild atm, but still healthy.
👍️0
The Night Stalker The Night Stalker 2 년 전
nice
👍️0
bme bme 2 년 전
Nice & Healthy.
👍️0
The Night Stalker The Night Stalker 2 년 전
quite the dip
👍️0
The Night Stalker The Night Stalker 2 년 전
ready
👍️0
The Night Stalker The Night Stalker 2 년 전
ready
👍️0
The Night Stalker The Night Stalker 2 년 전
red to green
👍️0
The Night Stalker The Night Stalker 2 년 전
red to green
👍️0
bme bme 2 년 전
Wonderful!
👍️0
The Night Stalker The Night Stalker 2 년 전
beauty
👍️0
The Night Stalker The Night Stalker 2 년 전
nice
👍️0
bme bme 2 년 전
Expect Q4 filing this week?
👍️0
bme bme 2 년 전
Be seeing that. Lot of 1.95 transactions so far
👍️0
TucsonPhil TucsonPhil 2 년 전
Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.
👍️0
bme bme 2 년 전
SP should be a lot higher since the Q4 revenue is more than double from last year...
👍️0
Welldoctor Welldoctor 2 년 전
Apparently insider buying reported on ST. Take it for what it’s worth.
👍️0
Welldoctor Welldoctor 2 년 전
RIGL news out
👍️0
bme bme 2 년 전
Looks like it will poke thru & bye bye 1 today.
👍️0
doesitreallymatter doesitreallymatter 2 년 전
Just like ABQQ. Right?
👍️0
subslover subslover 2 년 전
You are 1/2 way there!!!!
👍️0
KngmAz KngmAz 2 년 전
Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!
👍️0
KngmAz KngmAz 2 년 전
This is a $10.00 per share stock in the very near future - EASILY!!
👍️0
Alaska40 Alaska40 2 년 전
I just bought in. Seems like a good run could come in the near future.
👍️0
subslover subslover 2 년 전
Consolidating nicely on Continuation from last week!
👍️0
bcapps66 bcapps66 2 년 전
LOL!
👍️0
THEMASTERS_SON THEMASTERS_SON 2 년 전
GIVE ME MY $2DOLLAS…YA BUM
👍️0

최근 히스토리

NASDAQ
RIGL
Rigel Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지